4:28 PM
 | 
Jan 24, 2012
 |  BC Extra  |  Company News

Ipsen returns fipamezole rights to Santhera

Ipsen Group (Euronext:IPN) returned exclusive rights outside North America and Japan to Santhera Pharmaceuticals Holding AG (SIX:SANN) for Parkinson's disease (PD) therapy fipamezole ( JP-1730). According to Santhera,...

Read the full 131 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >